Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotech
From BioCentury This Week · · 33 min
This plays from the publisher's own server. We do not host a copy.
Description
Novartis is deepening its antibody-drug conjugate capabilities with its $1.1 billion acquisition of U.K. biotech Myricx Pharma. On the latest episode of the BioCentury This Week podcast, BioCentury’s analysts discuss how the deal fits with the Swiss pharma’s cancer toolkit. The analysts then discuss MHRA CEO Lawrence Tallon’s Guest Commentary (https://www.biocentury.com/article/659994) in BioCentury on making regulation a catalyst for U.K. life sciences and why the primary defeat (https://www.biocentury.com/article/660006) of Rep. Diana DeGette (D-Colo.) is a setback for FDA reforms. They also assess how single-cell Parkinson’s atlases (https://www.biocentury.com/article/659881) reveal neuronal and glial disruptions in specific regions and stages, and the thin evidence underpinning Congress’ probe (https://www.biocentury.com/article/659987) of China trial consent. This episode of the BioCentury This Week podcast has been brought to you by CBRE (https://www.cbre.com/).
View full story: https://www.biocentury.com/article/660033
#ADC #BiotechMA #ParkinsonsDisease #FDA #ChinaBiotech
00:01 - Sponsor Message: CBRE 01:15 - Novartis Buying Myricx 08:01 - U.K. Regulation 14:44 - DeGette & FDA Reform 21:51 - Parkinson's Atlas Insights 29:39 - China Trials Probe
To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.
Reach us by sending a text (https://www.buzzsprout.com/1035190/fan_mail/new)